The colorectal cancer coalition: Reflections on the future

Oncologist

Volumn 11, Issue 9, 2006, Pages 970-972

  Johnston, Patrick G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGO 41699; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DNA TOPOISOMERASE INHIBITOR; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; THYMECTACIN; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG SYNTHESIS; DRUG TOLERANCE; EDITORIAL; GENE EXPRESSION; HUMAN; METASTASIS; MICROARRAY ANALYSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL;

COLORECTAL NEOPLASMS; COMMUNITY HEALTH SERVICES; DATA COLLECTION; FORECASTING; HUMANS; MASS SCREENING; PATIENT EDUCATION;

EID: 33749817947     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-9-970     Document Type: Editorial

References (8)

1. Benson III AB. New approaches to the adjuvant therapy of colon cancer. The Oncologist 2006;11 :973-980.
2. Goldberg RM. Therapy for metastatic colorectal cancer. The Oncologist 2006;11:981-987.
3. Schmoll HJ., Arnold D. Update on capecitabine in colorectal cancer. The Oncologist 2006;11:1003-1009.
4. Ryan DP. Nonsurgical approaches to colorectal cancer. The Oncologist 2006;11:999-1002.
5. Van Cutsem E. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. The Oncologist 2006;11:1010-1017.
6. O'Dwyer, PJ. The present and future of angiogenesis-directed treatments of colorectal cancer. The Oncologist 2006;11:992-998.
7. Wilson R. Novel therapeutic developments other than EGFR and VEGF inhibition in colorectal cancer. The Oncologist 2006;11:1018-1024.
8. Harkin DP. Genomics and the impact of new technologies on the management of colorectal cancer. The Oncologist 2006;11:988-991.